Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Future Oncology

• Publication date

  2012-02-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2217/fon.11.147PMID 22335579PMCID PMC3292053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer.

  2011cited by this paper
• Low-dose-rate brachytherapy for treatment of uterine didelphys malignancy.

  2011cited by this paper
• Deoxynucleoside Salvage Facilitates DNA Repair During Ribonucleotide Reductase Blockade in Human Cervical Cancers

  2011cited by this paper
• Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.

  2011cited by this paper
• Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.

  2011cited by this paper
• Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer

  2010cited by this paper
• Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers

  2010cited by this paper
• Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate.

  2009cited by this paper
• Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced p53 Protein

  2009cited by this paper
• Methemoglobinemia: from diagnosis to treatment.

  2008cited by this paper
• Methemoglobinemia: from diagnosis to treatment.

  2008cited by this paper
• Methemoglobin—It's not just blue: A concise review

  2007cited by this paper
• Ribonucleotide reductase inhibitors and future drug design.

  2006cited by this paper
• Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

  2004cited by this paper
• A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

  2004influential reference
• Radiation sensitizers and targeted therapies.

  2003cited by this paper
• Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

  2003cited by this paper
• Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.

  2003cited by this paper
• Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

  2002cited by this paper
• Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells*

  2001cited by this paper
• Structure and function of the radical enzyme ribonucleotide reductase.

  2001cited by this paper
• A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

  2000cited by this paper
• An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans.

  1998cited by this paper
• Concise review: methemoglobinemia.

  1993cited by this paper
• Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators.

  1993cited by this paper
• Mechanism of action of hydroxyurea.

  1992cited by this paper
• Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

  1990cited by this paper
• Hemoglobin by first derivative spectrophotometry: extent of hemolysis in plasma and serum collected in vacuum container devices.

  1989cited by this paper
• Interactions between deoxyribonucleotide and DNA synthesis.

  1988cited by this paper
• Spurious pulse oximeter desaturation with methylene blue injection.

  1986cited by this paper
• Methaemoglobinaemia.

  1981cited by this paper
• Measuring percent oxygen saturation of hemoglobin, percent carboxyhemoglobin and methemoglobin, and concentrations of total hemoglobin and oxygen in blood of man, dog, and baboon.

  1980cited by this paper
• Reduction of ribonucleotides.

  1979cited by this paper
• Methaemoglobinaemia

  1952cited by this paper

• Isosteric Replacement of Sulfur to Selenium in a Thiosemicarbazone: Promotion of Zn(II) Complex Dissociation and Transmetalation to Augment Anticancer Efficacy.

  2024cites this paper
• Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

  2024cites this paper
• Innovative N-Acridine Thiosemicarbazones and Their Zn(II) Complexes Transmetallate with Cu(II): Redox Activity and Suppression of Detrimental Oxy-Myoglobin Oxidation.

  2024cites this paper
• TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress

  2022cites this paper
• In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

  2021cites this paper
• Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

  2021cites this paper
• Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes

  2021cites this paper
• Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints

  2019cites this paper
• Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers

  2019cites this paper
• Feline primary erythrocytosis: a multicentre case series of 18 cats

  2018cites this paper
• Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers

  2018cites this paper
• Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer

  2018cites this paper
• Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development

  2018cites this paper
• Triapine Radiochemotherapy in Advanced Stage Cervical Cancer

  2018cites this paper
• Selenotriapine – An isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-D mammary adenocarcinoma tumors

  2017cites this paper
• Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity

  2016cites this paper
• Differences in protein binding and excretion of Triapine and its Fe(III) complex.

  2016cites this paper
• Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

  2016cites this paper
• Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

  2016cites this paper
• The structural characterization and DNA binding of pyridyl-azo-acetylacetonato complexes of zinc(II), cadmium(II) and mercury(II)

  2015cites this paper
• DEVELOPMENT OF METHEMOGLOBIN-BASED BIOLOGICAL DOSIMETRY IN GAMMA–IRRADIATED MICE

  2015cites this paper
• The triage-type radiation dose

  2015cites this paper
• Nucleotide metabolism, oncogene-induced senescence and cancer.

  2015cites this paper
• Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia

  2014cites this paper
• Chapter 23 - Metal antagonists

  2014cites this paper
• Two Cases of Methemoglobinemia Induced by the Exposure to Nitrobenzene and Aniline

  2013cites this paper
• Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

  2013cites this paper